Systemic therapy of paediatric atopic dermatitis: An update

Australasian Journal of Dermatology

Volumn 49, Issue 3, 2008, Pages 123-134

  Borchard, Kate L A ^a   Orchard, David ^a  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

Antiallergics; Antibiotics; Antihistamines; ASM 981; Atopic eczema; Azathioprine; Biologic agents; Corticosteroids; Cyclosporin; Essential fatty acids; Immunoglobulin; Interferon; Leflunomide; Leukotriene antagonists; Methotrexate; Mycophenolate mofetil

Indexed keywords

ANTIALLERGIC AGENT; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; AZATHIOPRINE; CEFALEXIN; CHLORAMBUCIL; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN; DIPHENHYDRAMINE; DOXEPIN; EFALIZUMAB; ERYTHROMYCIN; ETANERCEPT; FLUCLOXACILLIN; FOLIC ACID; GAMMA INTERFERON; HYDROXYZINE; IMMUNOGLOBULIN; INFLIXIMAB; MEPOLIZUMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; OMALIZUMAB; PENICILLIN G; PIMECROLIMUS; PREDNISOLONE; PSEUDOMONIC ACID; TACROLIMUS; UNINDEXED DRUG; VRI 003;

ACANTHOSIS NIGRICANS; ACNE; ADRENAL CORTEX INSUFFICIENCY; AGITATION; ALOPECIA; ANAPHYLAXIS; ANEMIA; ARTERY DISEASE; ARTHRALGIA; ASEPTIC MENINGITIS; ASTHENIA; ATOPIC DERMATITIS; BLOOD TOXICITY; BLURRED VISION; BONE DENSITY; BONE MARROW SUPPRESSION; BONE NECROSIS; BRAIN PSEUDOTUMOR; CATARACT; CHILD GROWTH; CHILL; CHINESE MEDICINE; CHRONIC KIDNEY DISEASE; COGNITIVE DEFECT; CONGESTIVE HEART FAILURE; CONSTIPATION; CUSHING DISEASE; DEMYELINATING DISEASE; DEPRESSION; DIARRHEA; DISSEMINATED INTRAVASCULAR CLOTTING; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DYSPEPSIA; DYSURIA; ECZEMA; ENZYME BLOOD LEVEL; EPIDERMIS NECROSIS; EPIDURAL LIPOMATOSIS; ERECTILE DYSFUNCTION; ERYTHEMA; ERYTHEMA MULTIFORME; ERYTHEMA NODOSUM; EVENING DOSAGE; EYE INFECTION; FATIGUE; FEVER; FLU LIKE SYNDROME; FLUSHING; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; GLAUCOMA; GROWTH DISORDER; HEADACHE; HEALING IMPAIRMENT; HEART ARRHYTHMIA; HEART DISEASE; HEART PALPITATION; HERPES SIMPLEX; HERPES VIRUS INFECTION; HERPES ZOSTER; HIRSUTISM; HODGKIN DISEASE; HUMAN; HYPERESTHESIA; HYPEREXCITABILITY; HYPERGLYCEMIA; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRICHOSIS; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOTENSION; INCREASED APPETITE; INSOMNIA; INTERSTITIAL PNEUMONIA; INTESTINE PERFORATION; JUVENILE RHEUMATOID ARTHRITIS; KAPOSI SARCOMA; KIDNEY DISEASE; LACTOBACILLUS; LETHARGY; LEUKOPENIA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; LIVER TOXICITY; LUNG FIBROSIS; LYMPHOCYTOPENIA; LYMPHOMA; MACULOPAPULAR RASH; MALAISE; MELANOMA; MENSTRUAL IRREGULARITY; METHOTREXATE OSTEOPATHY; MOLLUSCUM CONTAGIOSUM; MOOD CHANGE; MULTIPLE ORGAN FAILURE; MUSCULOSKELETAL PAIN; MYALGIA; MYOPATHY; NAUSEA; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUTROPENIA; NONHODGKIN LYMPHOMA; NUMMULAR DERMATITIS; OPPORTUNISTIC INFECTION; OSTEOPOROSIS; PANCYTOPENIA; PARESTHESIA; PEPTIC ULCER; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PERSONALITY DISORDER; PHARYNGITIS; PHOTOTHERAPY; PHOTOTOXICITY; PNEUMONIA; PRURITUS; PSYCHOSIS; PURPURA; PUSTULAR PSORIASIS; PUVA; PYURIA; RASH; RECOMMENDED DRUG DOSE; REFRACTION ERROR; REMISSION; RESPIRATORY TRACT DISEASE; REVIEW; RHABDOMYOLYSIS; RIGOR; SEDATION; SERUM SICKNESS; SHOCK; SIDE EFFECT; SKIN ATROPHY; SKIN CANCER; SKIN CARCINOMA; SKIN INFECTION; SKIN PAIN; SKIN PIGMENTATION; SKIN TOXICITY; SOLID TUMOR; SOMNOLENCE; SPASTIC DIPLEGIA; SPASTICITY; STAPHYLOCOCCUS INFECTION; STEATOHEPATITIS; STOMATITIS; STRIA; SUICIDAL IDEATION; SYSTEMIC THERAPY; TACHYCARDIA; TELANGIECTASIA; TELOGEN EFFLUVIUM; TERATOGENICITY; THROMBOCYTOPENIA; TINNITUS; TREATMENT RESPONSE; TREMOR; TUBERCULOSIS; TUBULAR DYSFUNCTION; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; ULTRAVIOLET RADIATION; URINARY FREQUENCY; URINARY URGENCY; UROGENITAL TRACT CANCER; UROGENITAL TRACT DISEASE; URTICARIA; VASCULITIS; VERRUCA VULGARIS; VISUAL DISORDER; VOMITING; WEAKNESS; WEIGHT GAIN; WHEEZING; WITHDRAWAL SYNDROME; XEROSTOMIA;

ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; DERMATITIS, ATOPIC; FATTY ACIDS, ESSENTIAL; HISTAMINE H1 ANTAGONISTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MEDICINE, CHINESE TRADITIONAL; PHOSPHODIESTERASE INHIBITORS; PLANT EXTRACTS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 47349110139     PISSN: 00048380     EISSN: 14400960     Source Type: Journal    
DOI: 10.1111/j.1440-0960.2008.00451_1.x     Document Type: Review

References (61)

1. Buys L. Treatment options for atopic dermatitis. Am. Fam. Phys. 2007 75 : 1 8.
2. Goujon C, Berard F, Dahel K, Guillot I, Hennino A, Nosbaum A, Saad N, Nicolas JF. Methotrexate for treatment of adult atopic dermatitis. Eur. J. Dermatol. 2006 16 : 155 8.
3. Leung DYM, Bieber T. Atopic dermatitis. Lancet 2003 361 : 151 60.
4. Spergel JM, Paller AS. Atopic dermatitis and the atopic march. J. Allergy Clin. Immunol. 2003 112 : S118 27.
5. Almqvist C, Li Q, Britton WJ, Kemp AS, Xuan W, Tovey ER, Marks GB. Early predictors for developing allergic disease and asthma: examining separate steps in the 'allergic march'. Clin. Exp. Allergy 2007 37 : 1296 302.
6. Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat. Genet. 2006 36 : 441 6.
7. Lipozencic J, Wolf R. Atopic dermatitis: an update and review of the literature. Dermatol. Clin. 2007 25 : 605 12.
8. Rudikoff D. Atopic dermatitis. In : Lebwohl MG, Heymann WR, Berth-Jones J, Coulson I (eds). Treatment of Skin Disease: Comprehensive Therapeutic Strategies, 2nd edn. Philadelphia : Elsevier Ltd, 2006 62 8.
9. Murphy LA, Atherton DA. A retrospective evaluation of azathioprine in severe childhood atopic eczema, using thiopurine methyltransferase levels to exclude patients at high risk of myelosuppression. Br. J. Dermatol. 2002 147 : 308 15.
10. Sidbury R, Hanifin JM. Systemic therapy of atopic dermatitis. Clin. Exp. Dermatol. 2000 25 : 559 66.
11. Dadiant C, Orlow SJ. Treatment of children and adolescents with methotrexate, cyclosporine, and etanercept: review of the dermatologic and rheumatologic literature. J. Am. Acad. Dermatol. 2005 52 : 316 40.
12. Wolverton SE. Comprehensive Dermatologic Drug Therapy. Philadelphia : WB Saunders, 2001.
13. Harper JI, Ahmed I, Barclay G, Lacour M, Hoeger P, Cork MJ et al. Cyclosporine for severe childhood atopic dermatitis: short course versus continuous therapy. Br. J. Dermatol. 2000 142 : 52 8.
14. Laxer RM. Long-term toxicity of immune suppression in juvenile rheumatic diseases. Rheumatology 1999 38 : 743 6.
15. Berth-Jones J, Finlay AY, Zaki I, Tan B, Goodyear H, Lewis-Jones S et al. Cyclosporine in severe childhood atopic dermatitis: a multicenter study. J. Am. Acad. Dermatol. 1996 34 : 1016 21.
16. Murphy LA, Atherton DJ. Azathioprine as a treatment for severe atopic eczema in children with partial thiopurine methyl transferase (TPMT) deficiency. Pediatr. Dermatol. 2003 20 : 531 4.
17. Balasubramaniam P, Ilchyshyn A. Successful treatment of severe atopic dermatitis with methotrexate. Clin. Exp. Dermatol. 2005 30 : 435 56.
18. Weatherhead SC, Wahie S, Reynolds NJ, Meggitt SJ. An open-label, dose-ranging study of methotrexate for moderate-to-severe adult atopic eczema. Br. J. Dermatol. 2007 156 : 346 51.
19. Neuber K, Schwartz I, Itschert G, Diek AT. Treatment of atopic eczema with oral mycophenolate mofetil. Br. J. Dermatol. 2000 143 : 385 91.
20. Ogden S, Clayton TH, Goodfield MJD. Recalcitrant hand pompholyx: variable response to etanercept. Clin. Exp. Dermatol. 2005 31 : 129 56.
21. Farshidi A, Sadeghi P. Successful treatment of severe refractory atopic dermatitis with efalizumab. J. Drugs Dermatol. 2006 5 : 994 8.
22. Jacobi A, Antoni C, Manger B, Schuler G, Herti M. Infliximab in the treatment of moderate to severe atopic dermatitis. J. Am. Acad. Dermatol. 2005 52 (Suppl. 3 522 6.
23. Chan JL, Davis-Reed L, Boer Kimball A. Counter-regulatory balance: atopic dermatitis in patients undergoing infliximab infusion therapy. J. Drugs Dermatol. 2004 3 : 315 18.
24. Vestergaard C, Deleuran M, Kragballe K. Two cases of atopic dermatitis-like conditions induced in psoriasis patients treated with infliximab. J. Eur. Acad. Dermatol. Venereol. 2007 21 : 1 2.
25. Krathen RA, Hsu S. Failure of omalizumab for treatment of severe adult atopic dermatitis. J. Am. Acad. Dermatol. 2005 53 : 338 40.
26. Oldhoff JM, Darsow U, Werfel T, Katzer K, Wulf A, Laifaoui J et al. IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy 2005 60 : 693 6.
27. Menter A, Griffiths C. Efalizumab and Psoriasis. London : Current Medicine Group, 2006.
28. Gagnon L. Biologics may be less toxic than other medications. Dermatology Times, at http://www.modernmedicine.com (2006). (Accessed 9 Jun 2007 MA, Eichenfield LF. A treatment approach for atopic dermatitis. Pediatr. Ann. 2005 34 : 201 23.
29. Horowitz R, Reynolds S. New oral antihistamines in pediatrics. Pediatr. Emerg. Care 2004 20 : 143 8.
30. Cheigh NH. Managing a common disorder in children: atopic dermatitis. J. Pediatr. Health Care 2003 17 : 84 90.
31. Hoeger PH. Antimicrobial susceptibility of skin-colonising S. aureus strains in children with atopic dermatitis. Pediatr. Allergy Immunol. 2004 15 : 474 7.
32. Leung DYM, Boguniewicz M, Howell MD, Nomura I, Hamid QA. New insights into atopic dermatitis. J. Clin. Invest. 2004 113 : 651 7.
33. Bunikowski R, Staab D, Kussebi F, Bräutigam M, Weidinger G, Renz H, Wahn U. Low dose cyclosporine A microemulsion in children with severe atopic dermatitis: clinical and immunologic effects. Pediatr. Allergy Immunol. 2001 12 : 216 23.
34. Stone KD. Atopic diseases of childhood. Curr. Opin. Pediatr. 2003 15 : 495 511.
35. Arkwright PD, Daniel TO, Sanyal D, David TJ, Patel L. Age-related prevalence and antibiotic resistance of pathogenic staphylococci and streptococci in children with infected atopic dermatitis at a single-specialty centre. Arch. Dermatol. 2002 138 : 939 41.
36. Sheikh A, Strachan DP. The hygiene theory: fact or fiction? Curr. Opin. Otolaryngol. Head Neck Surg. 2004 12 : 232 6.
37. Prescott SL, Dunstan JA, Hale J, Breckler L, Lehmann H, Weston S, Richmond P. Clinical effects of probiotics are associated with increased interferon-γ responses in very young children with atopic dermatitis. Clin. Exp. Allergy 2005 35 : 1557 64.
38. Kalliomaki M, Salminen S, Poussa T, Arvilommi H, Isolauri E. Probiotics and prevention of atopic disease: 4-year follow-up of a randomized placebo-controlled trial. Lancet 2003 361 : 1869 71.
39. Dunstan JA, Hale J, Beckler L, Lehmann H, Weston S, Richmond P, Prescott SL. Atopic dermatitis in young children is associated with impaired interleukin-10 and interferon-γ responses to allergens, vaccines and colonizing skin and gut bacteria. Clin. Exp. Allergy 2005 35 : 1309 17.
40. Viljanen M, Savilahti E, Haahtela T, Juntunen-Backman K, Korpela R, Poussa T, Tuure T, Kuitunen M. Probiotics in the treatment of atopic eczema/dermatitis syndrome in infants: a double-blind placebo controlled trial. Allergy 2005 60 : 494 500.
41. Miraglia del Giudice M, De Luca MG. The role of probiotics in the clinical management of food allergy and atopic dermatitis. J. Clin. Gastroenterol. 2004 38 : S84 5.
42. Rosenfeldt V, Benfeldt E, Nielson SD, Michaelsen KF, Jeppesen DL, Valerius NH, Paerregaard A. Effect of probiotic Lactobacillus strains in children with atopic dermatitis. J. Allergy Clin. Immunol. 2003 111 : 389 95.
43. Liu AH. Consider the child: how early should we treat? J. Allergy Clin. Immunol. 2004 113 : S19 24.
44. Kalliomaki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E. Probiotics in primary prevention of atopic disease: a randomized placebo-controlled trial. Lancet 2001 357 : 1076 9.
45. Weston S, Halbert A, Richmond P, Prescott SL. Effects of probiotics on atopic dermatitis: a randomized controlled trial. Arch. Dis. Child 2005 90 : 892 7.
46. Prescott SL, Björkstén B. Probiotics for the prevention or treatment of allergic diseases. J. Allergy Clin. Immunol. 2007 120 : 255 62.
47. Tuchinda C, Kerr HA, Taylor CR, Jacobe H, Bergamo BM, Elmets C, Rivard J, Lim HW. Ultraviolet-A1 phototherapy for cutaneous diseases: an experience of 92 cases in the United States. Photodermatol. Photoimmunol. Photomed. 2006 22 : 247 53.
48. Pasic A, Ceovic R, Lipozencic J, Husar K, Susic SM, Skerlev M, Hrsan D. Phototherapy in pediatric patients. Pediatr. Dermatol. 2003 20 : 71 7.
49. Boguniewicz M, Eichenfield LF, Hultsch T. Current management of atopic dermatitis and interruption of the atopic march. J. Allergy Clin. Immunol. 2003 112 : S140 50.
50. Wolff K, Fleming C, Hanifin J, Papp K, Reitamo S, Rustin M et al. Efficacy and tolerability of three different doses of oral pimecrolimus in the treatment of moderate to severe atopic dermatitis: a randomized controlled trial. Br. J. Dermatol. 2005 152 : 1296 303.
51. Manna SK, Mukhopadhyay A, Aggarwal BB. Leflunomide inhibits TNF-induced cellular responses: effects on NFκB, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis. J. Immunol. 2000 165 : 5962 9.
52. Wozel G, Vitez L, Pfeiffer C. Severe atopic dermatitis and leflunomide: first clinical experience and highlights of pertinent experimental data. Dermatol. Online J. 2007 12 : 6.
53. Schmitt J, Wozel G, Pfeiffer C. Leflunomide as a novel treatment option in severe atopic dermatitis. Br. J. Dermatol. 2004 150 : 1182 5.
54. Lovell P, Vender RB. Management and treatment of pruritus. Skin Therapy Letter, vol. 12, no. 1, at http://www.skintherapyletter.com/2007/12.1/1.html (2007 Accessed 9 June 2007 R, Parekh N, Mangat I, Bhalerao S. Alleviating the itch-scratch cycle in atopic dermatitis. Psychosomatics 2005 46 : 373 4.
55. Metze D, Reimann S, Beissert S, Luger T. Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological diseases. J. Am. Acad. Dermatol. 1999 41 : 533 9.
56. Chari S, Clark-Loeser L, Shupack J, Washenik K. A role for leukotriene antagonists in atopic dermatitis? Am. J. Clin. Dermatol. 2001 2 : 1 6.
57. Rackal JM, Vender RB. The treatment of atopic dermatitis and other dermatoses with leukotriene antagonists. Skin Therapy Letter, vol. 9, no. 2, at http://www.skintherapyletter.com/2004/9.2/1.html (2004 Accessed 9 June 2007 CJAW, Zeegers MPA, Thijs C. Oral essential fatty acid supplementation in atopic dermatitis; a meta-analysis of placebo-controlled trials. Br. J. Dermatol. 2004 150 : 728 40.
58. Takwale A, Tan E, Agarwal S, Barclay G, Ahmed I, Hotchkiss K, Thompson JR, Chapman T, Berth-Jones J. Efficacy and tolerability of borage oil in adults and children with atopic eczema: randomized, double-blind, placebo-controlled, parallel group trial. BMJ 2003 327 : 1385 8.
59. Van Gool CJAW, Thijs C, Henquet CJM, Van Houwelingen AC, Dagnelie PC, Schrander J, Menheere PPCA, Van den Brandt PA. G-Linolenic acid supplementation for prophylaxis of atopic dermatitis; a randomized controlled trial in infants at high familial risk. Am. J. Clin. Nutr. 2003 77 : 943 51.
60. Koo J, Arain S. Traditional Chinese medicine for the treatment of dermatological disorders. Arch. Dermatol. 1998 134 : 1388 93.
61. Harper B. Traditional Chinese medicine for eczema. BMJ 1994 308 : 489 90.